$Amarin (AMRN.US)$
undervalued, oversold
C&E: 156M ST Debt: 9.5M, LT Debt: 8.88M CR: 3.2 QR: 2.08 FCF: -18M
The risk of dilution is low for now. However, cash burn is problematic. Expanded to Euro markets w/2039 patent expiry

$Amarin (AMRN.US)$
Amarin Receives National Reimbursement for VAZKEPA® in Italy
Monday, 16th December at 7:00 am
-- Italian Health Authorities Approve VAZKEPA® (icosapent ethyl) for National Reimbursement to Reduce Cardiovascular Risk in Eligible High-Risk Patients1 --
-- Italy is the Third EU5 Market to Grant National Reimbursement; Ninth National Reimbursement for VAZKEPA® Overall in Europe --
-- European Progress Has Advanced Patient Access: Countries That Have Provided Access to VAZKEP...

$Amarin (AMRN.US)$
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On November 22, 2024, Amarin Corporation plc (the “Company”) received a notice (the “Extension Notice”) from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that Nasdaq has granted the Company an additional 180 calendar days, or until May 19, 2025, to regain compliance with the minimum bid price requi...

$Amarin (AMRN.US)$ what will happen after November 20 if the price does not become more than 1 dollar?

$Amarin (AMRN.US)$  wat happen down for 15% again

$Amarin (AMRN.US)$ Bought 20k at $0.65

$Amarin (AMRN.US)$ Reported Saturday, New REDUCE-IT Analyses By Amarin Show That VASCEPA/VAZKEPA Benefits High-Risk Cardiovascular Disease Patient Subgroups

$Amarin (AMRN.US)$ Just thinking outloud

$Amarin (AMRN.US)$ Amarin Received Decision To Grant From European Patent Office For New Patent Covering VAZKEPA That Will Extend VAZKEPA Exclusivity Eight Additional Years Into 2039